EXOZ
eXoZymes, Inc.Healthcare · $57M market cap
Verdict
We can't put a fair value on EXOZ right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow EXOZ
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Aug 19, 2026: 5 open-market purchases worth $6K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Purchases
Heltzen Michael
Chief Executive Officer · 2026-08-26
Bought
$2K
Heltzen Michael
Chief Executive Officer · 2026-08-26
Bought
$2K
Heltzen Michael
Chief Executive Officer · 2026-08-26
Bought
$30
Heltzen Michael
Chief Executive Officer · 2026-08-25
Bought
$750
Heltzen Michael
Chief Executive Officer · 2026-08-25
Bought
$2K
Other filings
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works